---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-018537"
form_type: "8-K"
ticker: "JSPR"
cik: "0001788028"
company_name: "Jasper Therapeutics, Inc."
filed_at: "2023-03-08T23:59:59+00:00"
generated_at: "2026-06-18T08:39:20.900924+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Jasper Therapeutics FY2022 net loss $37.7M; expands briquilimab to chronic urticaria, raises $101.4M

## Summary
- FY2022 net loss $37.7M vs $30.6M in 2021; R&D $34.6M, G&A $16.6M.
- Cash $38.3M at Dec 31; raised $101.4M net in Jan 2023; expects funding through 2024.
- Expanding briquilimab to chronic spontaneous urticaria; 12/12 AML engraftment, 8/12 relapse-free at 1yr.
- Appointed Vishal Kapoor to board of directors.

## SEC filing metadata
- accession: 0001213900-23-018537
- form_type: 8-K
- ticker: JSPR
- cik: 0001788028
- company_name: Jasper Therapeutics, Inc.
- filed_at: 2023-03-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1788028/000121390023018537/0001213900-23-018537-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1788028/000121390023018537/ea174835-8k_jasper.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-018537
- JSON: https://secwatch.observer/filing/0001213900-23-018537.json
- Plain text: https://secwatch.observer/filing/0001213900-23-018537.txt

## Key facts
- Earnings Releases
  Jasper Therapeutics, Inc. reported the fiscal year ended December 31, 2022 results: net income Net loss was $37.7 million.
  - Period: the fiscal year ended December 31, 2022
  - Net income: Net loss was $37.7 million
  - Result: reported results
  source text: Jasper Therapeutics, Inc. issued a press release reporting its financial results for the fiscal year ended December 31, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1788028/000121390023018537/0001213900-23-018537-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.